ReCellience15
CompanyUnited States
ReCellience15 develops one asset, in phase 2 (pentadecanoic acid in biological aging). Mostly supplement acting on Mitochondrial biogenesis (PGC-1α), lipid and ceramide metabolism and inflammation; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 2
- Signals
Pipeline
1Essential odd-chain saturated fatty acid supplement supporting red blood cell membrane health and longevity
Phase 2, Supplement, Mitochondrial biogenesis (PGC-1α), Lipid and ceramide metabolism, biological aging, red blood cell health
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Signals3
- Similar companies6